Literature DB >> 32823393

Commentary: Clinical pearls and pitfalls in diagnosing viral anterior uveitis.

Uday Tekchandani1, Atul Arora1, Simar Rajan Singh1, Mohit Dogra1.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32823393      PMCID: PMC7690557          DOI: 10.4103/ijo.IJO_1397_20

Source DB:  PubMed          Journal:  Indian J Ophthalmol        ISSN: 0301-4738            Impact factor:   1.848


× No keyword cloud information.
We congratulate the authors on putting together a comprehensive review article that elaborately covers most aspects of viral anterior uveitis.[1] This manuscript should serve as a “ready reckoner” for all ophthalmologists who wish to gain information regarding diagnosis and management of patients with this enigmatic uveitic entity. We highlight a few points that would add to the vast ocean of knowledge on viral anterior uveitis that this article encompasses: While dealing with various causes of hypertensive anterior uveitis, importance of a thorough slit-lamp examination cannot be underestimated as presence/absence of subtle features helps to clinically elucidate the etiology. Absence of ciliary congestion with high intraocular pressure (IOP) is seen in both Posner–Schlossman syndrome (PSS) and Fuchs uveitis syndrome (FUS). When IOP and corneal edema (generally epithelial) are out of proportion to ciliary congestion in a patient with acute and recurrent unilateral granulomatous/non-granulomatous anterior uveitis with minimal anterior chamber reaction, a diagnosis of PSS can be made with reasonable certainty.[2] FUS has been termed as a microgranulomatous uveitis, with stellate keratic precipitates all over the corneal endothelium and presence of Koeppe's and Busacca's nodules (less commonly). Absence of ciliary congestion, minimal anterior chamber reaction, diffuse iris atrophy, absence of posterior synechiae, early posterior subcapsular cataract formation, and presence of vitreous membranes are characteristic findings which aid in differentiating FUS from other granulomatous anterior uveitic entities that warrant specific workup and targeted management[3] While examining a case of viral anterior uveitis, a dilated fundus examination with an indirect ophthalmoscope is mandatory so as not to miss peripheral lesions of acute retinal necrosis. Necrotizing viral retinopathies may be preceded by episcleritis/scleritis, periorbital pain, and/or anterior uveitis in about one-third cases[4] One of the recently reported causes of viral anterior uveitis with keratitis is mumps. Clinical features include intense photophobia, corneal edema with Descemet's folds, and severe endotheliitis with high IOP. Rapid decrease of corneal endothelial cell density is generally noted after resolution of corneal edema[5] Brimonidine should be used with caution to treat high IOP in patients of viral anterior uveitis. Brimonidine may cause granulomatous anterior uveitis which may mimic recurrence of viral anterior uveitis. This side-effect may present with or without symptoms, usually many months after initiation of treatment. It may occur only in unilaterally and is fully reversible once brimonidine is withdrawn[6] Resistance of herpes simplex virus (HSV) to acyclovir and cytomegalo virus (CMV) to ganciclovir is a recently reported phenomenon. HSV resistance to acyclovir occurs due to specific mutations in the viral thymidine kinase, mutations in the viral DNA polymerase gene, HSV having a deficient thymidine kinase protein or the natural hypervariability of HSV thymidine kinase gene. Acyclovir resistant HSV strains also show some amount of cross-resistance to ganciclovir which has implications in management of these patients. Use of cidofovir and foscarnet is recommended to treat acyclovir resistant HSV anterior uveitis.[7] Ganciclovir-resistant CMV occurs due to mutation in the UL97 gene that codes for phosphorylation of CMV viral kinase. Management of patients with ganciclovir resistant CMV is recommended with high dose ganciclovir, foscarnet, letermovir, leflunomide, and CMV-immunoglobulin.[8]

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  8 in total

1.  An Adult Case of Fulminant Mumps Keratitis With Positive Viral RNA in Aqueous Humor Detected by RT-PCR.

Authors:  Teppei Shibata; Yoriko Takahashi; Ayako Okamoto; Hiroshi Sasaki; Kazuko Kitagawa
Journal:  Cornea       Date:  2016-04       Impact factor: 2.651

Review 2.  Posner-Schlossman syndrome.

Authors:  Roly Megaw; Pankaj Kumar Agarwal
Journal:  Surv Ophthalmol       Date:  2016-12-22       Impact factor: 6.048

Review 3.  Diagnosis and Treatment of Acute Retinal Necrosis: A Report by the American Academy of Ophthalmology.

Authors:  Scott D Schoenberger; Stephen J Kim; Jennifer E Thorne; Prithvi Mruthyunjaya; Steven Yeh; Sophie J Bakri; Justis P Ehlers
Journal:  Ophthalmology       Date:  2017-01-13       Impact factor: 12.079

4.  Brimonidine Induced Anterior Uveitis.

Authors:  Jacqueline Beltz; Ehud Zamir
Journal:  Ocul Immunol Inflamm       Date:  2015-09-23       Impact factor: 3.070

5.  Acyclovir-resistant herpes simplex virus type 1 in intra-ocular fluid samples of herpetic uveitis patients.

Authors:  Monique van Velzen; Tom Missotten; Freek B van Loenen; Roland J W Meesters; Theo M Luider; G Seerp Baarsma; Albert D M E Osterhaus; Georges M G M Verjans
Journal:  J Clin Virol       Date:  2013-04-10       Impact factor: 3.168

Review 6.  Management of Ganciclovir Resistant Cytomegalovirus Retinitis in a Solid Organ Transplant Recipient: A Review of Current Evidence and Treatment Approaches.

Authors:  L Fu; K Santhanakrishnan; M Al-Aloul; N P Jones; L R Steeples
Journal:  Ocul Immunol Inflamm       Date:  2019-10-17       Impact factor: 3.070

Review 7.  A literature review on Fuchs uveitis syndrome: An update.

Authors:  Yang Sun; Yinghong Ji
Journal:  Surv Ophthalmol       Date:  2019-10-14       Impact factor: 6.048

Review 8.  Viral anterior uveitis.

Authors:  Kalpana Babu; Vinaya Kumar Konana; Sudha K Ganesh; Gazal Patnaik; Nicole S W Chan; Soon-Phaik Chee; Bianka Sobolewska; Manfred Zierhut
Journal:  Indian J Ophthalmol       Date:  2020-09       Impact factor: 1.848

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.